- Home
- MATH vs BDTX Comparison
MATH vs BDTX Comparison
Compare MATH & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MATH
- BDTX
- Stock Information
- Founded
- MATH 2015
- BDTX 2014
- Country
- MATH Hong Kong
- BDTX United States
- Employees
- MATH N/A
- BDTX N/A
- Industry
- MATH Finance/Investors Services
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MATH Finance
- BDTX Health Care
- Exchange
- MATH Nasdaq
- BDTX Nasdaq
- Market Cap
- MATH 60.8M
- BDTX 132.5M
- IPO Year
- MATH N/A
- BDTX 2020
- Fundamental
- Price
- MATH $3.66
- BDTX $2.56
- Analyst Decision
- MATH
- BDTX Strong Buy
- Analyst Count
- MATH 0
- BDTX 6
- Target Price
- MATH N/A
- BDTX $14.83
- AVG Volume (30 Days)
- MATH 237.8K
- BDTX 1.2M
- Earning Date
- MATH 08-26-2025
- BDTX 08-05-2025
- Dividend Yield
- MATH N/A
- BDTX N/A
- EPS Growth
- MATH N/A
- BDTX N/A
- EPS
- MATH 0.17
- BDTX 0.09
- Revenue
- MATH $31,399,049.00
- BDTX $70,000,000.00
- Revenue This Year
- MATH N/A
- BDTX N/A
- Revenue Next Year
- MATH N/A
- BDTX N/A
- P/E Ratio
- MATH $23.26
- BDTX $28.49
- Revenue Growth
- MATH 291.58
- BDTX N/A
- 52 Week Low
- MATH $0.80
- BDTX $1.20
- 52 Week High
- MATH $4.17
- BDTX $6.75
- Technical
- Relative Strength Index (RSI)
- MATH 58.37
- BDTX 59.61
- Support Level
- MATH $2.88
- BDTX $2.43
- Resistance Level
- MATH $3.97
- BDTX $2.72
- Average True Range (ATR)
- MATH 0.32
- BDTX 0.17
- MACD
- MATH 0.02
- BDTX -0.01
- Stochastic Oscillator
- MATH 75.28
- BDTX 75.77
About MATH Metalpha Technology Holding Limited
Metalpha Technology Holding Ltd is a digital asset focused wealth management company. The company predominantly generates revenue from the execution of cryptocurrency-related transactions, which includes the issuance of derivative products to over-the-counter (OTC) clients and its proprietary trading activities. It has partnered with a crypto exchange to provide crypto derivative market-making services for its clients, facilitating the trading of crypto derivative products. In addition, the company also engages in providing traditional financial derivative products, and asset management services. It operates in a single segment which is the trading of proprietary digital assets and derivative contracts, and derives a majority of its revenue from Hong Kong.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.